Furuland, Hans
McEwan, Phil
Evans, Marc
Linde, Cecilia
Ayoubkhani, Daniel
Bakhai, Ameet
Palaka, Eirini
Bennett, Hayley
Qin, Lei
Funding for this research was provided by:
AstraZeneca
Article History
Received: 2 May 2018
Accepted: 8 August 2018
First Online: 22 August 2018
Ethics approval and consent to participate
: Routinely collected, anonymised electronic health records from the Clinical Practice Research Datalink (CPRD) used as part of this study were provided by the Medicines and Healthcare Products Regulatory Agency (MHRA), an executive agency of the Department of Health & Social Care. This study was approved by the Independent Scientific Advisory Committee for MHRA database research on 15 December 2016 (study protocol 16_223R). Patient consent is covered by the CPRD privacy policy, available at ExternalRef removed . No other patient-level data were collected as part of this study.
: Not applicable.
: HF has received modest research grant funding from AstraZeneca (as principal investigator), and modest expert witness funding from Amgen (as consultant). PM, DA and HB have received significant research grant funding from AstraZeneca in relation to this study. ME declares no conflict of interest. CL has received significant research grant funding from AstraZeneca (awarded to institution), and modest speaker honoraria from Biotronik, Medtronic, Abbot, Novartis and Vifor. AB has received modest advisory honoraria from AstraZeneca in relation to this study. EP and LQ are full-time employees of AstraZeneca.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.